[{"NetIncomeLoss_1_Q1_USD":-70000.0,"StockholdersEquityNoteStockSplitConversionRatio1_1_Q1_pure":1.0,"NetIncomeLossAttributableToNoncontrollingInterest_1_Q1_USD":1489000.0,"GeneralAndAdministrativeExpense_1_Q1_USD":5156000.0,"WeightedAverageNumberOfShareOutstandingBasicAndDiluted_1_Q1_shares":41977336.0,"CommitmentsAndContingencies_0_Q1_USD":null,"ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_1_Q1_USD":1489000.0,"AccruedLiabilitiesCurrent_0_Q1_USD":6015000.0,"OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_1_Q1_USD":-58000.0,"RoyaltyExpense_1_Q1_USD":0.0,"NetCashProvidedByUsedInInvestingActivities_1_Q1_USD":-137726000.0,"StockIssuedDuringPeriodValueNewIssues_1_Q1_USD":264516000.0,"AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_0_Q1_USD":60000.0,"LesseeOperatingLeaseLiabilityPaymentsDueYearThree_0_Q1_USD":313000.0,"AssetsCurrent_0_Q1_USD":447293000.0,"OperatingLeaseExpense_1_Q1_USD":200000.0,"PaymentsToAcquireAvailableForSaleSecuritiesDebt_1_Q1_USD":149763000.0,"AccumulatedOtherComprehensiveIncomeLossNetOfTax_0_Q1_USD":-60000.0,"AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_1_Q1_shares":6853465.0,"Liabilities_0_Q1_USD":9967000.0,"CashAndCashEquivalentsAtCarryingValue_0_Q1_USD":293537000.0,"ShortTermInvestments_0_Q1_USD":147337000.0,"LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_0_Q1_USD":451000.0,"ResearchAndDevelopmentExpense_1_Q1_USD":12415000.0,"LesseeOperatingLeaseLiabilityPaymentsDue_0_Q1_USD":1990000.0,"MinorityInterest_0_Q1_USD":2798000.0,"AccruedBonusesCurrent_0_Q1_USD":563000.0,"PrepaidExpenseCurrent_0_Q1_USD":6419000.0,"AdditionalPaidInCapitalCommonStock_0_Q1_USD":560366000.0,"OtherNonoperatingIncomeExpense_1_Q1_USD":-2000.0,"CommonStockValue_0_Q1_USD":4000.0,"DepreciationDepletionAndAmortization_1_Q1_USD":15000.0,"NetCashProvidedByUsedInFinancingActivities_1_Q1_USD":264580000.0,"ProceedsFromSaleAndMaturityOfMarketableSecurities_1_Q1_USD":12037000.0,"ComprehensiveIncomeNetOfTax_1_Q1_USD":-128000.0,"IncreaseDecreaseInAccountsPayable_1_Q1_USD":-4124000.0,"OtherAssetsNoncurrent_0_Q1_USD":147000.0,"IncomeTaxExpenseBenefit_1_Q1_USD":0.0,"StockIssuedDuringPeriodValueShareBasedCompensation_1_Q1_USD":3508000.0,"LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_0_Q1_USD":618000.0,"OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_1_Q1_USD":-58000.0,"LongTermInvestments_0_Q1_USD":32111000.0,"DeferredRentCreditNoncurrent_0_Q1_USD":73000.0,"RetainedEarningsAccumulatedDeficit_0_Q1_USD":-93409000.0,"CommonStockSharesOutstanding_0_Q1_shares":43516125.0,"AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_0_Q1_USD":2000.0,"NetCashProvidedByUsedInOperatingActivities_1_Q1_USD":-1515000.0,"LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_0_Q1_USD":608000.0,"AvailableForSaleDebtSecuritiesAmortizedCostBasis_0_Q1_USD":179506000.0,"LiabilitiesCurrent_0_Q1_USD":9894000.0,"AccountsPayableCurrent_0_Q1_USD":3879000.0,"OtherAccruedLiabilitiesCurrent_0_Q1_USD":91000.0,"IncomeLossAttributableToNoncontrollingInterest_1_Q1_USD":-1500000.0,"AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_1_Q1_USD":22870000.0,"CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_0_Q1_USD":293537000.0,"StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_0_Q1_USD":469699000.0,"PropertyPlantAndEquipmentNet_0_Q1_USD":115000.0,"CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_1_Q1_USD":125339000.0,"StockholdersEquity_0_Q1_USD":466901000.0,"DeferredOfferingCosts_0_Q1_USD":2700000.0,"ProfitLoss_1_Q1_USD":1419000.0,"CommonStockSharesIssued_0_Q1_shares":43516125.0,"AvailableForSaleSecuritiesDebtSecurities_0_Q1_USD":179448000.0,"Assets_0_Q1_USD":479666000.0,"ShareBasedCompensation_1_Q1_USD":3508000.0,"CommonStockParOrStatedValuePerShare_0_Q1_USD":0.0001,"IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_1_Q1_USD":4352000.0,"CommonStockSharesAuthorized_0_Q1_shares":150000000.0,"RevenueFromContractWithCustomerExcludingAssessedTax_1_Q1_USD":18943000.0,"OperatingIncomeLoss_1_Q1_USD":1372000.0,"ProceedsFromIssuanceInitialPublicOffering_1_Q1_USD":267268000.0,"InvestmentIncomeInterest_1_Q1_USD":49000.0,"LiabilitiesAndStockholdersEquity_0_Q1_USD":479666000.0,"DividendsPayableCurrentAndNoncurrent_0_Q1_USD":0.0,"AllocatedShareBasedCompensationExpense_1_Q1_USD":3508000.0,"DeferredTaxAssetsValuationAllowance_0_Q1_USD":0.0,"OperatingExpenses_1_Q1_USD":17571000.0,"EarningsPerShareBasicAndDiluted_1_Q1_USD":0.0,"AccruedProfessionalFeesCurrent_0_Q1_USD":851000.0,"ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_1_Q1_USD":1361000.0,"Ticker":"CGEM","CIK":"1789972","name":"CULLINAN ONCOLOGY, INC.","OfficialName":"Cullinan Oncology Inc. Common Stock","form":"10-Q","period":"20210331","fy":"2021.0","fp":"Q1","qtrs":"1","uom":"USD","footnote":"nan","Market Cap":"494263432.0","Country":"United States","Sector":"Health Care","Industry":"Biotechnology: Pharmaceutical Preparations","Market":"NASDAQ","SP500":"nan","filed":"20210514"}]